Quantum-Si Incorporated: financial analysis
Ratios worked out from 8 fiscal years of Quantum-Si Incorporated's statements, compared with 665 companies in Biotechnology.
Quantum-Si Incorporated scorecard#
Passes 2 of the 15 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 21, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.8×.
- ✗Price to sales below its peers' median200.7×Price to sales 200.7× against Biotechnology's median of 8.6×.
- ✗Free cash flow yield above 5%-38.1%Free cash flow is -38.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 3
- ✗Revenue grew in the newest year-20.3%Revenue down 20.3% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.51 vs -0.71Diluted EPS -0.51 in fiscal 2025 against -0.71 the year before (report's currency).
- ✗Net income higher than five years earlier-$101 M-$101 M in fiscal 2025 against -$37 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$101 MNet income -$101 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-46.5%-46.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities7.6×Current ratio 7.64 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone1.24Z-score 1.24 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year38.1%Diluted shares up 38.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Revenue fell 20.3% against the year before.
- Net loss of $101 million, the 7th loss-making year in a row.
- Free cash flow was negative: -$97 million.
- The share count rose 38.1% in the year.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseno
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.62 | × 1.2 | 0.75 |
| Retained earnings to assets | -2.84 | × 1.4 | -3.98 |
| Operating income to assets | -0.47 | × 3.3 | -1.56 |
| Market value to liabilities | 10.04 | × 0.6 | 6.03 |
| Revenue to assets | 0.01 | × 1 | 0.01 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 47.1% | 52.3% | 45.4% | — | — | 74.8% | 20% | |
| Return on equity | -46.5% | -41.5% | -30.5% | -31.7% | -59.9% | -61.0% | 61% | |
| Return on assets | -41.1% | -37.0% | -27.8% | -29.6% | -34.9% | -44.4% | 54% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -20.3% | 183.3% | — | — | — | 15.8% | 19% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.64× | 11.99× | 22.94× | 22.80× | 41.39× | 4.39× | 68% | |
| Equity share of assets | 89.7% | 86.9% | 91.1% | 91.6% | 94.8% | 64.7% | 85% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-97 M | $-92 M | $-99 M | $-101 M | $-73 M | $-40 M | 27% | |
| Capital spending share of revenue | 103.3% | 149.7% | 417.6% | — | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.01× | 0.01× | 0.00× | — | — | 0.26× | 1% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).